
Quanterix Corp — Investor Relations & Filings
Quanterix Corporation is a company focused on digitizing biomarker analysis to advance the science of precision health. Its core offering is the proprietary Simoa® technology, an ultra-sensitive digital immunoassay platform designed to detect and measure biomarkers at extremely low concentrations. This capability allows researchers to study the biology of health and disease with high precision, enabling earlier disease detection, improved prognoses, and the development of more effective treatment methods. The Simoa platform is utilized across a wide range of therapeutic areas, including a strategic focus on neurology (neurodegeneration, neuroinflammation, traumatic brain injuries), as well as oncology, cardiology, inflammation, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-26 | English | |
| 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | |
| ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | |
| 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47073899 | 8-K | 2026-05-26 | English | ||
| 41998200 | 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | ||
| 36127788 | ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 36127820 | DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 33034998 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | ||
| 32968563 | 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32968562 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32892834 | 10-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892833 | 8-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892832 | 4 - QUANTERIX CORP (0001503274) (Filer) | 2026-02-18 | English | ||
| 30191110 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30191109 | 4 Filing | 2026-02-06 | English | ||
| 30191105 | 4 Filing | 2026-01-21 | English | ||
| 30191104 | 3 Filing | 2026-01-21 | English | ||
| 30191111 | 4 Filing | 2026-01-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Burning Rock Biotech Ltd
A global diagnostics company specializing in precision onco…
|
BNR | US | Professional, scientific and te… |
|
Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated au…
|
CABA | US | Professional, scientific and te… |
|
Caliway
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
Quanterix Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33531/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33531 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33531 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33531 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33531}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Quanterix Corp (id: 33531)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.